BCL2 and cancer: Furthermore, BER shows synergistic effects with anticancer agents celecoxib, trichostatin A and carmofur on inhibiting the growth of MDA-MB-231 cells and reducing the ratio of Bcl-2/Bax and/or VEGF expressions in the cancer cells.